RIPK1 Inhibition Enhances Pirarubicin Cytotoxic Efficacy through AKT-P21-dependent Pathway in Hepatocellular Carcinoma

Pirarubicin (THP) is a new generation cell cycle nonspecific anthracycline anticancer drug. Pirarubicin and pirarubicin-based combination therapies have been demonstrated to be effective against HCC in TACE. However, the drug resistance limits its therapeutic efficacy. Receptor-interacting protein k...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hechen, Chen, Tianchi, Zhou, Yuan, Geng, Lei, Shen, Tian, Zhou, Lin, Zheng, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299408/
https://www.ncbi.nlm.nih.gov/pubmed/30588188
http://dx.doi.org/10.7150/ijms.28289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299408/
https://www.ncbi.nlm.nih.gov/pubmed/30588188
http://dx.doi.org/10.7150/ijms.28289

Ejemplares similares